Periostin and Treatment Responsiveness in Asthma: A Prospective Cohort Study with Imaging-Based Airway Remodeling Assessment and PAI-1 Promoter Polymorphism Analysis

未提供0 个研究点目标入组 75 人开始时间: 待定

适应症

试验速览

暂无简介。

•Patients diagnosed with bronchial asthma.
•Patients meeting the criteria for moderate-to-severe persistent asthma according to JGL
•Adults aged 18 years or older who regularly attend the outpatient clinic of the Department of Respiratory Medicine, Nagasaki University Hospital.
•Patients who have received high-dose inhaled corticosteroid (ICS)-based therapy (in combination with LABA, LAMA, LTRA and or biologic agents, as applicable) during the period from 1 September 2025 to 31 March
•Patients who are able to provide written informed consent.

•Patients with a diagnosis of chronic lung disease other than asthma, such as chronic obstructive pulmonary disease (COPD) or diffuse interstitial lung disease.
•Patients who are pregnant or breastfeeding.
•Patients with terminal malignancy or progressive severe systemic disease (e.g., severe heart failure, end-stage renal disease on dialysis).
•Patients who are unable to provide consent due to a strong aversion or fear of blood sampling and/or genetic testing.
•Patients deemed inappropriate for study participation by the attending physician or the principal investigator (e.g., expected difficulty in cooperation/adherence).

发起方

未提供